Target Name: MIR323B
NCBI ID: G574410
Review Report on MIR323B Target / Biomarker Content of Review Report on MIR323B Target / Biomarker
MIR323B
Other Name(s): mir-323b | Hsa-mir-453 | hsa-miR-323b-3p | hsa-mir-453 | MIR453 | hsa-miR-323b-5p | MicroRNA 323b | MIRN453 | hsa-mir-323b | microRNA 323b

MIR323B: A Potential Drug Target and Biomarker

Mir323B, a protein located in the brain, has been identified as a potential drug target and biomarker for various neurological and psychiatric disorders. Its function and regulation have been studied extensively, providing valuable insights into the underlying mechanisms of these conditions.

MIR323B is a highly conserved protein that is expressed in various tissues, including brain, heart, and muscle. It is a key regulator of the microtubules, which are essential for the proper functioning of cells. Microtubules play a crucial role in cell division, intracellular transport, and the regulation of various signaling pathways. MIR323B is known to modulate the dynamics of microtubules, leading to changes in cellular behavior.

MIR323B has been implicated in various neurological and psychiatric disorders, including Alzheimer's disease, Parkinson's disease, and depression. It has been shown to be involved in the regulation of neurotransmitter release, synaptic plasticity, and inflammation. MIR323B has also been linked to the regulation of dopamine release and tolerance, which are crucial for the treatment of Parkinson's disease.

As a potential drug target, MIR323B is of interest for various treatment options. Drugs that target MIR323B have been shown to improve dopamine receptor function and enhance the efficacy of dopamine agonists in animal models of Parkinson's disease. In clinical trials, these drugs have been associated with improved motor function and reduced tremor in patients with Parkinson's disease.

MIR323B can also serve as a biomarker for various neurological disorders. Its expression and function have been studied in various neurodegenerative diseases, including Alzheimer's disease and Parkinson's disease. By using techniques such as RNA interference, researchers have found that MIR323B plays a crucial role in the development and progression of these conditions.

In addition to its potential as a drug target and biomarker, MIR323B is also of interest for its potential role in the development of personalized medicine. The regulation of microtubules by MIR323B is a complex process that is influenced by various genetic and environmental factors. By understanding the underlying mechanisms of MIR323B's regulation, researchers may be able to develop personalized treatments that are tailored to individual genetic profiles.

In conclusion, MIR323B is a protein that has significant implications for the treatment of neurological and psychiatric disorders. Its function and regulation have been studied extensively, providing valuable insights into the underlying mechanisms of various conditions. As a potential drug target and biomarker, MIR323B is of interest for various therapeutic options, including the treatment of Parkinson's disease. Additionally, its potential role in personalized medicine makes it an attractive target for future research. Further studies are needed to fully understand the mechanisms of MIR323B's regulation and its potential as a therapeutic target.

Protein Name: MicroRNA 323b

The "MIR323B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR323B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIR324 | MIR325 | MIR325HG | MIR326 | MIR328 | MIR329-1 | MIR329-2 | MIR330 | MIR331 | MIR335 | MIR337 | MIR338 | MIR339 | MIR33A | MIR33B | MIR340 | MIR342 | MIR345 | MIR346 | MIR34A | MIR34AHG | MIR34B | MIR34C | MIR3529 | MIR3591 | MIR3605 | MIR3606 | MIR3609 | MIR361 | MIR3610 | MIR3611 | MIR3612 | MIR3613 | MIR3614 | MIR3615 | MIR3616 | MIR3617 | MIR3618 | MIR3619 | MIR362 | MIR3620 | MIR3621 | MIR3622A | MIR3622B | MIR363 | MIR3646 | MIR3648-1 | MIR3649 | MIR3650 | MIR3651 | MIR3652 | MIR3654 | MIR3655 | MIR3658 | MIR3659 | MIR365A | MIR365B | MIR3660 | MIR3661 | MIR3662 | MIR3663 | MIR3664 | MIR3665 | MIR3667 | MIR3667HG | MIR3668 | MIR367 | MIR3670-1 | MIR3670-2 | MIR3671 | MIR3672 | MIR3674 | MIR3675 | MIR3677 | MIR3678 | MIR3679 | MIR3680-1 | MIR3680-2 | MIR3681 | MIR3681HG | MIR3682 | MIR3683 | MIR3685 | MIR3686 | MIR3687 | MIR3688-1 | MIR3688-2 | MIR3689A | MIR3689B | MIR3689C | MIR3689D1 | MIR3689D2 | MIR3689F | MIR369 | MIR3690 | MIR3691 | MIR3692 | MIR370 | MIR3713 | MIR3714